0001599298-24-000070.txt : 20240415 0001599298-24-000070.hdr.sgml : 20240415 20240415092146 ACCESSION NUMBER: 0001599298-24-000070 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240411 FILED AS OF DATE: 20240415 DATE AS OF CHANGE: 20240415 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ronaghi Mostafa CENTRAL INDEX KEY: 0001441876 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36866 FILM NUMBER: 24843294 MAIL ADDRESS: STREET 1: 9885 TOWNE CENTRE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Summit Therapeutics Inc. CENTRAL INDEX KEY: 0001599298 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2882 SAND HILL ROAD STREET 2: SUITE 106 CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-460-8308 MAIL ADDRESS: STREET 1: 2882 SAND HILL ROAD STREET 2: SUITE 106 CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: Summit Therapeutics plc DATE OF NAME CHANGE: 20150219 FORMER COMPANY: FORMER CONFORMED NAME: Summit Corp plc DATE OF NAME CHANGE: 20140205 4 1 wk-form4_1713187295.xml FORM 4 X0508 4 2024-04-11 0 0001599298 Summit Therapeutics Inc. SMMT 0001441876 Ronaghi Mostafa C/O SUMMIT THERAPEUTICS INC. 601 BRICKELL KEY DRIVE, SUITE 1000 MIAMI FL 33131 1 0 0 0 0 Stock Option (right to buy) 4.03 2024-04-11 4 A 0 200000 A 2034-04-11 Common Stock 200000 200000 D Stock Option (right to buy) 4.03 2024-04-11 4 A 0 25315 A 2034-04-11 Common Stock 25315 225315 D The option was granted on April 11, 2024. The shares underlying the option shall vest in four equal annual installments, with the first such installment occurring on April 11, 2025, subject to the director remaining as a non-salaried director on each such vesting date. Not applicable. The option was granted on April 11, 2024 and represents a pro rata amount of the annual 35,000 option board grant based approximately on the number of days the reporting person is anticipated to serve as a director in 2024. The shares underlying the option are scheduled to vest in full on December 31, 2024, subject to the director remaining as a non-salaried director on such vesting date. /s/ Bhaskar Anand, as Attorney-in-Fact for Mostafa Ronaghi 2024-04-15